Overexpression of the GR Riborepressor LncRNA GAS5 Results in Poor Treatment Response and Early Relapse in Childhood B-ALL.
ALL IC-BFM
BFM
childhood leukemia
glucocorticoid receptor
glucocorticoids
growth arrest-specific 5
leukemia
long non-coding RNA
non-coding RNA
pediatric leukemia
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
received:
29
10
2021
revised:
21
11
2021
accepted:
24
11
2021
entrez:
10
12
2021
pubmed:
11
12
2021
medline:
11
12
2021
Statut:
epublish
Résumé
Glucocorticoids (GCs) remain the cornerstone of childhood acute lymphoblastic leukemia (chALL) therapy, exerting their cytotoxic effects through binding and activating of the glucocorticoid receptor (GR). GAS5 lncRNA acts as a potent riborepressor of GR transcriptional activity, and thus targeting GAS5 in GC-treated chALL could provide further insights into GC resistance and support personalized treatment decisions. Herein, to study the clinical utility of GAS5 in chALL prognosis and chemotherapy response, GAS5 expression was quantified by RT-qPCR in bone marrow samples of chB-ALL patients at diagnosis (
Identifiants
pubmed: 34885174
pii: cancers13236064
doi: 10.3390/cancers13236064
pmc: PMC8656629
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2010 Nov;11(11):1096-106
pubmed: 20947430
Nat Commun. 2014 Nov 07;5:5395
pubmed: 25377354
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Front Endocrinol (Lausanne). 2017 Feb 06;8:16
pubmed: 28220107
Sci Signal. 2010 Feb 02;3(107):ra8
pubmed: 20124551
Adv Exp Med Biol. 2015;872:315-33
pubmed: 26216001
J Clin Oncol. 2014 Jan 20;32(3):174-84
pubmed: 24344215
PLoS One. 2011;6(10):e25915
pubmed: 21991387
Lancet. 2020 Apr 4;395(10230):1146-1162
pubmed: 32247396
PLoS One. 2013;8(1):e55684
pubmed: 23383264
J Med Biochem. 2019 May 11;38(3):292-298
pubmed: 31156339
Haematologica. 2020 Sep 10;105(11):2524-2539
pubmed: 33054110
Cell. 2013 Jul 3;154(1):26-46
pubmed: 23827673
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Front Immunol. 2019 Jul 04;10:1545
pubmed: 31333672
Mamm Genome. 1998 Sep;9(9):773-4
pubmed: 9716666
Front Oncol. 2021 Mar 11;11:617937
pubmed: 33777761
Nat Rev Genet. 2016 Jan;17(1):47-62
pubmed: 26666209
Cell Rep. 2020 Jul 21;32(3):107933
pubmed: 32697996
J Cell Sci. 2008 Apr 1;121(Pt 7):939-46
pubmed: 18354083
Oncol Lett. 2020 May;19(5):3431-3438
pubmed: 32269616
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3120-5
pubmed: 10077647
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
Nature. 2018 Jan 4;553(7686):96-100
pubmed: 29258294
Clin Cancer Res. 2011 Aug 1;17(15):4936-41
pubmed: 21593194
Cell. 1988 Sep 9;54(6):787-93
pubmed: 3409319
N Engl J Med. 2015 Oct 15;373(16):1541-52
pubmed: 26465987
Blood. 2008 Dec 15;112(13):4793-807
pubmed: 19064739
Cancer. 2017 Dec 15;123 Suppl 24:5178-5189
pubmed: 29205314
Genes (Basel). 2015 Jul 07;6(3):484-99
pubmed: 26198250
Br J Cancer. 2018 Dec;119(12):1477-1486
pubmed: 30374124
Front Physiol. 2017 Nov 02;8:814
pubmed: 29163187
Stem Cell Res Ther. 2018 Mar 21;9(1):71
pubmed: 29562912
Genes Dev. 2007 Aug 1;21(15):1833-56
pubmed: 17671086
N Engl J Med. 2006 Jan 12;354(2):166-78
pubmed: 16407512
Trends Pharmacol Sci. 2013 Sep;34(9):518-30
pubmed: 23953592
J Clin Oncol. 2015 Sep 20;33(27):2938-48
pubmed: 26304874
Mol Pharmacol. 2010 Jul;78(1):19-28
pubmed: 20421347
Oncogenesis. 2019 Nov 18;8(12):68
pubmed: 31740660
J Natl Compr Canc Netw. 2020 Jan;18(1):81-112
pubmed: 31910389
Lancet. 2013 Jun 1;381(9881):1943-55
pubmed: 23523389
Leukemia. 2000 Dec;14(12):2205-22
pubmed: 11187912
Biomed Res Int. 2013;2013:358015
pubmed: 24319682
Int J Mol Sci. 2020 Oct 15;21(20):
pubmed: 33076450
Mol Cell Biol. 1998 Dec;18(12):6897-909
pubmed: 9819378